{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:42:30Z","timestamp":1771555350019,"version":"3.50.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>The high-dose glucocorticosteroid (GC) treatment is the first choice for dermatomyositis complicated with interstitial lung disease (DM-ILD) but patients are resistant to the high-dose GC monotherapy. Besides, the high dose of GC, the secondary immunosuppressive agent(s) is necessary but there is controversy for the selection of immunosuppressive agent(s). The objectives of the study were to analyze the efficacy of different therapeutic options for DM-ILD to identify the optimal therapy. A total of 60 patients had received intravenous 1.0\u20132.0\u200amg\/\u200akg\/day prednisolone for DM-ILD. In severe conditions, patients had received oral 1 to 3\u200amg\/day tacrolimus (TAC), 500\u200amg\/\u200am<jats:sup>2<\/jats:sup>\/month cyclophosphamide (CY), and\/or 1\u200ag\/ day methylprednisolone pulse (TI cohort, n\u200a=\u200a24). In severe conditions, patients had received 1\u200ag\/day methylprednisolone pulse and 2\u20133\u200amg\/\u200akg\/day cyclosporine A (CsA) and\/or 500\u200amg\/\u200am<jats:sup>2<\/jats:sup>\/month CY (existing historical treatment; CT cohort, n\u200a=\u200a36). Patients of the TI cohort did not receive CsA. Patients in the CT cohort were received CY in significantly fewer numbers than those of the TI cohort during treatment (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.0112). A total of 11 (46%) patients from the TI cohort and 14 (39%) patients from the CT cohort were developed relapsed. At the end of the 30-months, higher numbers of patients of the TI cohort had an event(s) free survival than those of the CT cohort (7 (29%) vs 2 (6%), <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.0229). Also, higher numbers of patients of the TI cohort had survived irrespective of an event(s) than those of the CT cohort (21 (87%) vs 22 (61%), <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.0399). Patients of the TI cohort had developed herpes zoster (2 (8%)) and cytomegalovirus (4 (17%)) infections. Patients of the CT cohort developed renal dysfunction (10 (28%)). Hyperglycemia, hyperlipidemia, and fracture (GC-related toxicities) were also reported in both cohorts and these toxicities were fever in the TI cohort. The addition of TAC to high doses GC with CY is an ideal treatment for severe conditions of DM-ILD (Level of Evidence: III; Technical Efficacy Stage: 4).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029108","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T13:06:32Z","timestamp":1655471192000},"page":"e29108","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Combination therapy of tacrolimus, high doses of glucocorticosteroids, and cyclophosphamide against existing historical treatment for patients in severe conditions of interstitial lung diseases complicated with dermatomyositis"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8484-3715","authenticated-orcid":false,"given":"Li","family":"Lian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-4334","authenticated-orcid":false,"given":"Mu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7792-7021","authenticated-orcid":false,"given":"Yingchun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5459-7688","authenticated-orcid":false,"given":"Kang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1295-5811","authenticated-orcid":false,"given":"Shengqian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"R1-20250612","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/rheumatology\/kev192","article-title":"The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis","volume":"54","author":"Kurita","year":"2015","journal-title":"Rheumatology"},{"key":"R2-20250612","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1002\/art.30513","article-title":"Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: A series of 107 patients","volume":"63","author":"Marie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R3-20250612","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"Mira-Avendano","year":"2013","journal-title":"Respir Med"},{"key":"R4-20250612","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/rheumatology\/kez394","article-title":"Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis\/dermatomyositis: a single-arm clinical trial","volume":"59","author":"Takada","year":"2020","journal-title":"Rheumatology"},{"key":"R5-20250612","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3109\/14397595.2015.1029239","article-title":"Corticosteroid-sparing effect of tacrolimus in the initial treatment of dermatomyositis and polymyositis","volume":"25","author":"Yokoyama","year":"2015","journal-title":"Mod Rheumatol"},{"key":"R6-20250612","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pupt.2015.12.004","article-title":"Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease","volume":"36","author":"Witt","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"key":"R7-20250612","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/1756-185X.12931","article-title":"Advantage of administering tacrolimus for improving prognosis of patients with polymyositis and dermatomyositis","volume":"19","author":"Ueno","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"R8-20250612","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/RHU.0000000000000487","article-title":"Effective use of calcineurin inhibitor in combination therapy for interstitial lung disease in patients with dermatomyositis and polymyositis","volume":"23","author":"Shimojima","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"R9-20250612","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.semarthrit.2019.12.001","article-title":"Performance of the new EULAR\/ACR classification criteria for idiopathic inflammatory myopathies (IIM) in a large monocentric IIM cohort","volume":"50","author":"Barsotti","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R10-20250612","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1186\/1471-2474-13-228","article-title":"Coadministration of tacrolimus with corticosteroid accelerates recovery in refractory patients with polymyositis\/dermatomyositis: a retrospective study","volume":"13","author":"Shimojima","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"R11-20250612","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter Prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R12-20250612","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: A randomized, open-label trial","volume":"26","author":"Fujisawa","year":"2021","journal-title":"Respirology"},{"key":"R13-20250612","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000345988","article-title":"Mechanisms of cyclosporine-induced renal cell apoptosis: A systematic review","volume":"37","author":"Xiao","year":"2013","journal-title":"Am J Nephrol"},{"key":"R14-20250612","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3899\/jrheum.191008","article-title":"Long-term safety and effectiveness of tacrolimus in patients with lupus nephritis: 5-year interim postmarketing surveillance study in Japan (TRUST)","volume":"48","author":"Takeuchi","year":"2021","journal-title":"J Rheumatol"},{"key":"R15-20250612","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10067-014-2803-z","article-title":"Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review","volume":"34","author":"Ge","year":"2015","journal-title":"Clin Rheumatol"},{"key":"R16-20250612","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1007\/s10067-015-3065-0","article-title":"The efficacy of tacrolimus in patients with refractory dermatomyositis\/polymyositis: A systematic review","volume":"34","author":"Ge","year":"2015","journal-title":"Clin Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:00:10Z","timestamp":1749754810000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029108"}},"subtitle":["A retrospective analysis"],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":16,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029108","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"2021-10-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}